Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8543199 | 0.89 | AR (0.62) | ARALDH1A1PGRCYP19A1SLC22A12 | |
| SCHEMBL5503879 | 0.86 | AR (0.62) | ARALDH1A1L3MBTL1PGRSLC22A12 | |
| SCHEMBL30360746 | 0.85 | AR (0.72) | ARALDH1A1L3MBTL1HTTTDP1 | |
| SCHEMBL19231170 | 0.85 | AR (0.72) | ARALDH1A1L3MBTL1HTTTDP1 | |
| SCHEMBL4174837 | 0.84 | AR (0.58) | ARALDH1A1L3MBTL1PGRCYP19A1 | |
| SCHEMBL4184922 | 0.83 | AR (0.65) | ARALDH1A1PGRCYP19A1SLC22A12 | |
| SCHEMBL474005 | 0.82 | AR (0.68) | ARPGRSLC22A12TRPV4 | |
| SCHEMBL7073821 | 0.81 | AR (0.55) | ARALDH1A1PGRCYP19A1SLC22A12 | |
| SCHEMBL15096347 | 0.81 | AR (0.66) | ARALDH1A1L3MBTL1HTTTDP1 | |
| SCHEMBL27376756 | 0.81 | AR (0.61) | ARALDH1A1PGRCYP19A1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | claimed |
| EP-1781280-A2 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2007-05-09 | — | — | EP | claimed |
| WO-2006018723-A2 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-23 | — | — | WO | claimed |
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105349-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | AR 1/4885ALDH1A1 1349/4885L3MBTL1 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.